Gilead Sciences, Inc. to Post FY2028 Earnings of $8.73 Per Share, Leerink Partnrs Forecasts (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDFree Report) – Investment analysts at Leerink Partnrs issued their FY2028 earnings per share (EPS) estimates for Gilead Sciences in a research report issued to clients and investors on Wednesday, February 7th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of $8.73 for the year. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.35 per share.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 39.45% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.67 EPS.

A number of other research analysts have also recently commented on GILD. Barclays boosted their price objective on Gilead Sciences from $82.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Gilead Sciences in a research note on Thursday, November 9th. They set a “hold” rating and a $75.00 price objective on the stock. Wells Fargo & Company cut their price target on Gilead Sciences from $90.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Wednesday. UBS Group cut their price target on Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 8th. Finally, Royal Bank of Canada cut their price target on Gilead Sciences from $78.00 to $76.00 and set a “sector perform” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Hold” and an average price target of $87.00.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Trading Down 0.8 %

Shares of GILD opened at $73.80 on Thursday. The stock’s 50-day moving average is $80.82 and its two-hundred day moving average is $78.22. The stock has a market cap of $91.96 billion, a PE ratio of 16.40, a P/E/G ratio of 0.92 and a beta of 0.20. Gilead Sciences has a 12 month low of $72.87 and a 12 month high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.34 and a quick ratio of 1.20.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently made changes to their positions in the stock. ING Groep NV grew its holdings in shares of Gilead Sciences by 96.6% during the fourth quarter. ING Groep NV now owns 931,968 shares of the biopharmaceutical company’s stock valued at $75,499,000 after purchasing an additional 457,847 shares during the last quarter. Manchester Capital Management LLC boosted its position in shares of Gilead Sciences by 0.9% during the fourth quarter. Manchester Capital Management LLC now owns 21,842 shares of the biopharmaceutical company’s stock worth $1,769,000 after buying an additional 185 shares during the period. Kentucky Retirement Systems Insurance Trust Fund boosted its position in shares of Gilead Sciences by 2.8% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 44,391 shares of the biopharmaceutical company’s stock worth $3,596,000 after buying an additional 1,222 shares during the period. NDVR Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $226,000. Finally, Kentucky Retirement Systems boosted its position in shares of Gilead Sciences by 3.1% during the fourth quarter. Kentucky Retirement Systems now owns 99,697 shares of the biopharmaceutical company’s stock worth $8,076,000 after buying an additional 3,008 shares during the period. 82.33% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Johanna Mercier sold 8,242 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total transaction of $702,465.66. Following the completion of the transaction, the insider now directly owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be issued a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.17%. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s payout ratio is currently 66.67%.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.